BRCA1 and neoplasm: In case of chemotherapy, synthetic lethality could emerge, increasing tumour control by the treatment and thereby improving patient survival, a similar synthetic lethal effect as observed for BRCA1-deficient breast tumours treated with PARP inhibitors [11, 13, 38].